Perrigo PRGO
NYSE PRGO
$13.72 -0.24 (-1.76%)
As of: Aug 20, 2026 · 3:59 PM EDT

Perrigo (PRGO) Cash from Investing Activities (2013 - 2026)

Perrigo (PRGO) posted quarterly Cash from Investing Activities of -$12.4 million for Q1 2026, up 51.75% year-over-year from -$8.2 million in Q1 2025, and up 49.39% quarter-over-quarter from -$24.5 million in Q4 2025.

Perrigo (PRGO) Cash from Investing Activities (2013 - 2026) Analysis & Trends

Perrigo (PRGO) has reported Cash from Investing Activities for 14 consecutive years, with -$12.4 million the latest figure, recorded in Q1 2026.

  • In Q1 2026, Cash from Investing Activities rose 51.75% year-over-year to -$12.4 million; the TTM figure through Mar 2026 stood at -$62.1 million (down 181.07% YoY), while the FY2025 annual figure was -$75.4 million, down 195.69% from the prior year.
  • Cash from Investing Activities grew to -$12.4 million in Q1 2026 per PRGO's latest filing, from -$24.5 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $212.7 million in Q3 2024 and bottomed at -$2.0 billion in Q3 2022.
  • Historically, Cash from Investing Activities has averaged -$120.3 million across 5 years, with a median of -$22.8 million in 2023.
  • Annual changes were most pronounced in 2022 — Cash from Investing Activities sank 8956.88% — and 2024, when it soared 792.83%.
  • Perrigo's Cash from Investing Activities stood at -$26.0 million in 2022, then increased by 12.31% to -$22.8 million in 2023, then slumped by 62.72% to -$37.1 million in 2024, then soared by 33.96% to -$24.5 million in 2025, then jumped by 49.39% to -$12.4 million in 2026.
  • Business Quant data shows PRGO's Cash from Investing Activities at -$12.4 million in Q1 2026, -$24.5 million in Q4 2025, and -$21.4 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Investing Activities (Qtr)
1 Haleon 43.83 Bn 42.86 Bn - -
2 Teva Pharmaceutical Industries 42.87 Bn 39.22 Bn 2.15 Bn -491.00 Mn
3 Zoetis 31.41 Bn 29.73 Bn 1.05 Bn -300.00 Mn
4 Takeda Pharmaceutical 28.55 Bn 22.75 Bn 5.10 Bn -550.24 Mn
5 United Therapeutics 22.08 Bn 19.42 Bn 683.80 Mn 87.50 Mn
6 Viatris 18.73 Bn 17.84 Bn 1.46 Bn -51.60 Mn
7 Neurocrine Biosciences 15.44 Bn 15.05 Bn 935.80 Mn -135.40 Mn
8 Elanco Animal Health 11.75 Bn 11.22 Bn 798.00 Mn -110.00 Mn
9 Dr Reddys Laboratories 10.11 Bn 9.94 Bn - -
10 Perrigo 1.91 Bn 1.51 Bn 313.90 Mn 349.40 Mn

Historic Data

Download Data
DateValue
Jun 27, 2026 349.40 Mn
Jun 27, 2026 349.40 Mn
Mar 28, 2026 -12.40 Mn
Mar 28, 2026 -12.40 Mn
Dec 31, 2025 -24.50 Mn
Dec 31, 2025 -24.50 Mn
Sep 27, 2025 -21.40 Mn
Sep 27, 2025 -21.40 Mn
Jun 28, 2025 -3.80 Mn
Jun 28, 2025 -3.80 Mn
Mar 29, 2025 -25.70 Mn
Mar 29, 2025 -25.70 Mn
Dec 31, 2024 -37.10 Mn
Dec 31, 2024 -37.10 Mn
Sep 28, 2024 212.70 Mn
Sep 28, 2024 212.70 Mn
Jun 29, 2024 -73.30 Mn
Jun 29, 2024 -73.30 Mn
Mar 30, 2024 -23.50 Mn
Mar 30, 2024 -23.50 Mn